Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it
will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day,
hosted by the Alliance for Regenerative Medicine, to be held in New York City
on March 21, 2019. Unique to the medical and biotech communities, the investor
conference focuses on fast-paced, concise presentations from more than 35
companies, consolidated to a one-day conference while allowing opportunities
for one-on-one partnering with venture and strategic investors. Genprex’s
presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the
Main Bar Room of the Metropolitan Club, One East 60th Street, New York, NY
10022. “I’m looking forward to attending Cell & Gene Therapy Investor Day
for the first time, with the opportunity to share information about Genprex’s
mission and our gene therapy technologies,” Genprex President and COO Julien
Pham, MD, MPH said in the news release. “With a wide array of companies and
industry leaders all presenting in a single day, this conference enables us and
the investment community to take the pulse of where the industry is heading. It
is an incredible honor to be a part of this event.”
To view the full press release, visit http://ibn.fm/BhatA
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
